Providence St. Joseph Health Digital Commons
Not a member yet
12290 research outputs found
Sort by
Leading Nurses to Become Informed and Intelligently Engage: Association of California Nurse Leaders\u27 Health Policy Work.
No full textThe Association of California Nurse Leaders (ACNL) Health Policy Committee (Committee) plays a vital role in advancing the political competency and policy engagement of nurse leaders throughout California. The Committee promotes informed, skilled, and empowered nursing professionals prepared to influence health policy through strategic initiatives grounded in education, competency development, legislative monitoring, and advocacy. Aligned with ACNL\u27s strategic priorities, the Committee operates through specialized subcommittees dedicated to developing policy competencies, educational offerings, and legislative updates. Evidence underscores the persistent underrepresentation of nurses in policy arenas and highlights the urgent need for structured development pathways to cultivate leadership and advocacy skills. Case examples demonstrate the Committee\u27s success in supporting nurses\u27 progression from novice participants to influential policy leaders. The work of the ACNL Health Policy Committee illustrates how nursing organizations can serve as effective vehicles for health policy engagement, ultimately strengthening the profession\u27s impact on health care systems. Nurse leaders are called upon to actively engage in policy advocacy, leverage their expertise, and guide the next generation of nurse advocates. This manuscript aims to showcase the impact of the Committee and serve as a model for other professional organizations to mobilize resources to empower nurse leaders. A call to action is issued to engage nurses at all levels of leadership in shaping equitable, effective health policy
International consensus recommendations and alignment of terminology for the histopathological diagnosis of extranodal extension in head and neck squamous cell carcinoma: an HN-CLEAR initiative.
No full textHistopathologically detected extranodal extension leads to upstaging and treatment escalation in head and neck squamous cell carcinoma. There is considerable variation in the prevalence of histopathologically detected extranodal extension in comparable studies. The Head and Neck Cancer International Group, which includes 23 organisations managing patients with head and neck cancer, identified several challenges in evaluating histopathologically detected extranodal extension. Thus, the Head and Neck Consensus Language for Ease and Reproducibility (HN-CLEAR) and its global stakeholders prioritised developing diagnostic criteria and uniform terminology for histopathologically detected extranodal extension. The histopathologically detected extranodal extension working group established by WHO, International Collaboration on Cancer Reporting, American Joint Committee on Cancer, Union for International Cancer Control, North American Society of Head and Neck Pathology, and American Academy of Oral and Maxillofacial Pathology committees undertook consensus deliberations using scanned whole slides and a PRISMA literature review-based scoping questionnaire. The guidelines were tested by 30 additional pathologists across six continents and strengthened with prescriptive diagnostic criteria and unifying terminology based on the inter-rater concordance analyses. This Review generates practically useful consensus diagnostic recommendations and aligned terminology for addressing the gaps in the histopathologically detected extranodal extension literature. The recommendations can be used globally and cater to all levels of medical resources, practices, and experiences, thus ensuring equitable patient care
Clinical Reasoning: A 21-Year-Old Patient Presenting With Penile Hemidystumescence.
No full textThis case presents a 21-year-old male patient with recurrent episodes of lost consciousness that exhibited both features of seizure and syncope that were ultimately diagnosed as syncope secondary to autonomic seizures. Notably, review of systems revealed stereotyped erectile dysfunction, characterized by unilateral penile tumescence ( hemidystumescence ) occurring peri-ictally. Neurologic workup revealed left temporal slowing on EEG, and antiseizure medication led to resolution of both the loss-of-consciousness events and the hemidystumescence. This case represents a novel manifestation of focal epilepsy, suggesting that stereotyped erectile dysfunction may hold localizing value
The University of California San Diego Post-Treatment Glioblastoma (UCSD-PTGBM) annotated multimodal MRI Dataset.
No full textWe present the University of California San Diego post-treatment glioblastoma (UCSD-PTGBM) annotated multimodal MRI dataset. The UCSD-PTGBM dataset includes 243 timepoints on 178 subjects with histopathologically-proven glioblastoma who were imaged with an advanced brain tumor protocol on 3 Tesla MRI scanners. Sequences include standard 3D imaging, as well as multishell diffusion (Restricted Spectrum Imaging, RSI) and perfusion imaging techniques (Arterial Spin Labelling, ASL and Dynamic Susceptibility Contrast, DSC), and neuroradiologist approved voxelwise tumor segmentations for both traditional segmentation masks and cellular tumor segmentations. The dataset also includes isocitrate dehydrogenase (IDH) mutation status and O6-methylguianine-DNA methyl-transferase (MGMT) promotor methylation status, as well as overall survival and progression free survival information for a subset of cases. We hope that researchers around the world will use these data to continue to improve analysis of post-operative MRI on glioblastoma patients, translate their findings into clinical practice and improve the management and outcome for these patients
Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial.
No full textCD19-negative relapse occurs in ~30% of persons with relapsed or refractory large B cell lymphoma (LBCL) who respond to axicabtagene ciloleucel (axi-cel; CD19-directed chimeric antigen receptor (CAR) T cell therapy). In this phase 2 single-arm study, 26 participants with chemorefractory LBCL received axi-cel in combination with rituximab. The primary endpoint was investigator-assessed complete response rate; select secondary endpoints included duration of response (DOR), axi-cel pharmacokinetics and safety. The complete response rate was 73%. Median DOR was 26.0 months; 46% of participants had an ongoing response at data cutoff. Peak CAR T cell (normalized by tumor burden) and rituximab area-under-the-curve levels were elevated in participants with complete or ongoing response. Axi-cel plus rituximab treatment led to durable responses with no new safety signals despite persistent B cell aplasia and pharmacokinetics of axi-cel were unaffected, indicating that dual targeting of CD19 and CD20 is a feasible and safe approach to potentially limit antigen escape. ClinicalTrials.gov registration: NCT04002401
The Lived Experiences of Registered Nurses in the ICU in Utilizing a Novel Prophylactic Clear Sacral Gel Dressing
No full text
